Experimental skin cream RLS-1496 shows 2-year biological age reduction in early trial

Rubedo Life Sciences reports its topical senolytic RLS-1496 cleared senescent cells and reduced skin biological age by two years in a four-week trial, with collagen up 10%. The findings are from a small early-stage study, and independent replication and long-term safety data are lacking. If validated, this would mark a first-in-class topical senolytic with potential implications for aging research and the cosmetics market.